Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer

Anne Weng Ekmann-Gade; Claus Kim Hogdall; Svend Aage Engelholm; Carsten Lindberg Fago-Olsen

doi:10.21873/anticanres.14248

Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer

Anne Weng Ekmann-Gade, Claus Kim Hogdall, Svend Aage Engelholm, Carsten Lindberg Fago-Olsen

Department of Oncology

3 Citations (Scopus)

Abstract

BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC).

PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity.

RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005).

CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.

Original language	English
Journal	Anticancer Research
Volume	40
Issue number	5
Pages (from-to)	2765-2770
Number of pages	6
ISSN	0250-7005
DOIs	https://doi.org/10.21873/anticanres.14248
Publication status	Published - May 2020

Keywords

Aged
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm/drug effects
Female
Humans
Logistic Models
Middle Aged
Multivariate Analysis
Neoadjuvant Therapy
Neoplasm Staging
Ovarian Neoplasms/drug therapy
Platinum/pharmacology

Access to Document

10.21873/anticanres.14248

Cite this

@article{f055809ebec6416bada2cb962682d4e9,

title = "Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer",

abstract = "BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC).PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity.RESULTS: The study population included 521 patients, of which 371 (71\%) and 150 (29\%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005).CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.",

keywords = "Aged, Chemotherapy, Adjuvant, Drug Resistance, Neoplasm/drug effects, Female, Humans, Logistic Models, Middle Aged, Multivariate Analysis, Neoadjuvant Therapy, Neoplasm Staging, Ovarian Neoplasms/drug therapy, Platinum/pharmacology",

author = "Ekmann-Gade, \{Anne Weng\} and Hogdall, \{Claus Kim\} and Engelholm, \{Svend Aage\} and Fago-Olsen, \{Carsten Lindberg\}",

year = "2020",

month = may,

doi = "10.21873/anticanres.14248",

language = "English",

volume = "40",

pages = "2765--2770",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "5",

}

TY - JOUR

T1 - Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer

AU - Ekmann-Gade, Anne Weng

AU - Hogdall, Claus Kim

AU - Engelholm, Svend Aage

AU - Fago-Olsen, Carsten Lindberg

PY - 2020/5

Y1 - 2020/5

N2 - BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC).PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity.RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005).CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.

AB - BACKGROUND/AIM: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC).PATIENTS AND METHODS: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity.RESULTS: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005).CONCLUSION: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.

KW - Aged

KW - Chemotherapy, Adjuvant

KW - Drug Resistance, Neoplasm/drug effects

KW - Female

KW - Humans

KW - Logistic Models

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoadjuvant Therapy

KW - Neoplasm Staging

KW - Ovarian Neoplasms/drug therapy

KW - Platinum/pharmacology

UR - https://www.scopus.com/pages/publications/85084276374

U2 - 10.21873/anticanres.14248

DO - 10.21873/anticanres.14248

M3 - Journal article

C2 - 32366422

SN - 0250-7005

VL - 40

SP - 2765

EP - 2770

JO - Anticancer Research

JF - Anticancer Research

IS - 5

ER -

Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this